Videos

Chad Tang, MD, discusses ongoing challenges for the treatment of patients with oligometastatic prostate cancer.

Expert panelists consider how they might apply data from the EMERALD study in their real-world management of HR+/HER2- metastatic breast cancer.

A focused review of data from the EMERALD study, which tested elacestrant, an oral SERD, in patients with HR+/HER2- metastatic breast cancer.

Jonathan C. Trent, MD, PhD, discusses why it is necessary for patients with gastrointestinal stromal tumors to have comprehensive testing to find actionable genomic alterations.

The results of a phase 1b trial looking at the use of acalabrutinib for patients with treatment-naive or relapsed/refractory mantle cell lymphoma has provided the support needed for the phase 3 ECHO study of this treatment.

An expert medical oncologist reviews recent data updates on lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Robert J. Motzer, MD, provides an overview of the CLEAR trial investigating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Corey Cutler explains the ROCKstar clinical trial of belumosudil for steroid-refractory chronic GVHD.

Experienced hematologist-oncologists offer their clinical experiences with ruxolitinib.

Cyrus M. Khan, MD, discusses the issues with PI3K inhibitor trials in patients with chronic lymphocytic leukemia and the potential role of these drugs.

A review of fam-trastuzumab deruxtecan nxki shows how it has become a standard of care for patients with metastatic breast cancer that is HER2-positive.

In light of the second-line treatment armamentarium for patients with HR+/HER2- metastatic breast cancer, expert oncologists discuss the selection and sequencing of specific agents in this setting.

Joyce O’Shaughnessy, MD, highlights key data from a number of clinical trials in the second-line treatment setting of HR+/HER2- metastatic breast cancer.

Barbara Buttin, MD, discusses the PAOLA-1 clinical trial and it impact on the first-line treatment of ovarian cancer.

Ruchi Garg, MD, discusses several important ongoing studies of targeted therapies in patients with recurrent endometrial cancer.

Michael T. Tees, MD, discusses the data behind ALLO-501A, an allogeneic chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma.

Rohan Garje, MD, explains some of the differences between the sarcomatoid and classic carcinoma of the bladder.

Yi-Bin Chen reviews data from the REACH3 trial of ruxolitinib in patients with chronic steroid-refractory graft versus host disease.

The panel discusses the iNTERGRATE trial of ibrutinib in combination with prednisone as frontline therapy for chronic GVHD.

Eric A. Singer, MD, MS, discusses which patients he believes would benefit most from adjuvant therapy for high-risk renal cell carcinoma.

Concluding the discussion, Dr Rana McKay discusses the current state of advanced RCC, potential breakthroughs, and best practices for optimal patient outcomes.

Rana McKay, MD, provides insights into decision-making strategies and consideration for treatment sequencing in advanced RCC.

Discussion on triplet therapy regimens in advanced RCC and how progressing therapeutic studies can impact its future use.

Yi Lin MD, PhD explains how results from CARTITUDE-1 impact the treatment landscape for relapsed or refractory multiple myeloma.

Expert perspective on CheckMate 9ER quality of life data and treatment implications for patients with advanced RCC.

Centering discussion on the CheckMate 9ER trial, Dr. McKay shares perspective of recent follow-up data of nivolumab + cabozantinib in frontline advanced RCC.

Reflection on biomarkers, treatment resistance, and other unmet needs in 1L treatment of advanced RCC by Rana R. McKay, MD.

Dr Rana McKay provides insight on preferred therapeutic options for first-line treatment of RCC and how patient risk stratification influences decision making.

Rana R. McKay, MD, reflects on the landscape of advanced RCC, discusses histology, subsets of kidney cancer, and IMDC criteria for prognostic stratification.

Dr. Florez and Dr. Sabari delve into areas of progress, unmet needs, and future research in NSCLC, encompassing novel biomarkers and targeted therapies such as CEACAM5.